ARK Invest reshaped several positions in early September 2026, directing tens of millions of dollars toward Rocket Lab and continuing to accumulate Intellia Therapeutics while reducing exposure to Meta Platforms and a group of biotechnology and technology companies.
Rocket Lab becomes a major focus
Three ARK exchange-traded funds purchased approximately $45 million worth of Rocket Lab shares between August 31 and September 8. The buying came after the space company’s stock fell nearly 60% from its all-time high of $151 reached earlier this year.
Rocket Lab reported second-quarter revenue growth of 62% year over year and a record backlog worth $2.36 billion. The company also secured $437 million in new bookings since March 31. Chief Executive Peter Beck described demand for launch services as “hideous,” while management said available launch slots beyond 2029 are “extraordinarily little.”
Rocket Lab is also seeking to acquire Iridium, the satellite communications company that operates 66 satellites and serves more than 2.5 million subscribers. ARK’s purchases suggest the firm is treating Rocket Lab as a long-term space infrastructure investment.
Meta position reduced
ARK sold a combined $27.9 million of Meta Platforms shares through two funds on September 9. Meta’s stock was trading about 18% below its record high at the time.
Meta’s appeal for ARK remains tied to its scale and artificial intelligence strategy. The company reaches 3.6 billion daily users across its applications, while using AI to improve advertising targeting and content recommendations. Meta reported 28% year-over-year revenue growth in the second quarter, and Chief Executive Mark Zuckerberg said its advertising business was expanding faster than that of any other company on a dollar basis.
Meta plans capital expenditures of between $165 billion and $169 billion in 2026. Its shares were trading at a forward price-to-earnings ratio above 21, with ARK apparently weighing the company’s heavy AI spending against the potential for stronger free cash flow over time.
Biotech and technology sales
On September 11, ARK sold 46,015 shares of Twist Bioscience through its ARKK ETF, worth approximately $5.8 million. The firm has been reducing its Twist position for several weeks.
Other sales included 60,556 shares of 10X Genomics, valued at roughly $4 million, and 121,217 shares of Bullish, worth about $4.1 million. ARK also trimmed smaller positions in Tempus AI, GeneDx Holdings and Alphabet.
At the same time, ARK purchased nearly 115,000 shares of Intellia Therapeutics for approximately $1.4 million. The transaction extended a recent pattern of buying in the gene-editing company.
ARK maintains an aggressive growth strategy
ARK’s flagship ARKK ETF was up about 9% in 2026, although it continued to trail the broader market. Four other ARK funds had outperformed the S&P 500 over the preceding three years.
The latest transactions show a continued preference for companies linked to artificial intelligence, biotechnology and space infrastructure, even as ARK reduces or reallocates positions in established technology and life-sciences holdings.

